|
Jun 12
|
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
|
|
Apr 17
|
Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
|
|
Apr 16
|
Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
|
|
Mar 14
|
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
|
|
Feb 28
|
Psychedelic: GH Research, Compass Pathways report earnings results
|
|
Jan 2
|
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
|
|
Oct 10
|
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
|
|
Aug 29
|
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
|
|
Jul 31
|
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
|
|
Jun 11
|
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
|
|
Apr 30
|
Clearmind Applies to Cease Being a Reporting Issuer in Canada
|
|
Feb 11
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
|
Jan 16
|
Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND)
|
|
Jan 16
|
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
|
|
Jan 11
|
Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
|
|
Jan 10
|
Clearmind Medicine Completed Type A Meeting with the FDA
|
|
Dec 5
|
Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
|
|
Dec 1
|
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
|
|
Nov 28
|
Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
|
|
Nov 27
|
Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
|